Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of Clinical Oncology …

Posted: Published on June 1st, 2013

This post was added by Dr. Richardson

HENDERSON, Nev.--(BUSINESS WIRE)--

Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in oncology and hematology, today announced key presentations of clinical data that included: three ZEVALIN (ibritumomab tiuxetan)-related poster presentations, and one oral presentation and two poster presentations of clinical data for belinostat at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, from May 31 to June 4, 2013.

For more information about the ASCO annual meeting and for a complete list of abstracts, please refer to the conference Web site at http://abstract.asco.org/.

The following are the key ZEVALIN and belinostat-related abstracts being presented at the ASCO conference:

Sunday June 2, 2013, 8:00 AM 11:45 AM Central Time

S Hall A2

S Hall A2

S Hall A2

Tuesday June 4, 2013, 8:00 AM 12:00 PM Central Time

About ZEVALINand the ZEVALIN Therapeutic Regimen

Go here to read the rest:
Spectrum Pharmaceuticals Highlights Six Abstracts of Clinical Data at the 2013 American Society of Clinical Oncology ...

Related Posts
This entry was posted in FDA Stem Cell Trials. Bookmark the permalink.

Comments are closed.